Term
| Insulin lispro is what type of drug? |
|
Definition
| Ultra-Short Acting Insulin |
|
|
Term
| Insulin aspart is what type of drug? |
|
Definition
| Ultra-Short Acting Insulin |
|
|
Term
|
Definition
| Ultra-Short Acting Insulin |
|
|
Term
|
Definition
| Short Acting Insulin Preparation |
|
|
Term
| What drug is a Recombinant that is identical to human insulin? |
|
Definition
|
|
Term
| Regular insulin Needs to be given.... |
|
Definition
| 30 to 45 minutes before meals |
|
|
Term
|
Definition
| intermediate acting insulin |
|
|
Term
| NPH is a complex of ___ & __ |
|
Definition
|
|
Term
| What does NPH Require for absorption? |
|
Definition
| proteolytic degradation of protamine for absorption of insulin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| HbA1c target should be < or = __ |
|
Definition
|
|
Term
| Fasting Self-monitored glucose should be < ___ mg/dl |
|
Definition
|
|
Term
| Post-prandial glucose (self-monitored) should be < ___-___ mg/dl |
|
Definition
|
|
Term
| ______-_____ units/kg/day- titrated to glycemic targets |
|
Definition
|
|
Term
|
Definition
| 1st generation sulfonylurea |
|
|
Term
|
Definition
| 1st generation sulfonylurea |
|
|
Term
|
Definition
| 1st generation sulfonylurea |
|
|
Term
|
Definition
| 2nd generation sulfonylurea |
|
|
Term
|
Definition
| 2nd generation sulfonylurea |
|
|
Term
|
Definition
| 2nd generation sulfonylurea |
|
|
Term
| Sulfonylureas: Mechanism of Action: |
|
Definition
Block ATP-sensitive K+ channel
Leads to depolarization and influx of Ca++
Results in insulin secretion |
|
|
Term
| "Extrapancreatic Effects” of sulfonylureas MOA unknown (2) |
|
Definition
1.) SUs indirectly increase tissue sensitivity to insulin, i.e., help overcome insulin resistance
2.) Help suppress hepatic glucose output |
|
|
Term
| longest acting sulfonylurea? |
|
Definition
|
|
Term
| _______ sulfonylurea w/ highest frequency of side effects, including hypoglycemia (related to t ½) |
|
Definition
|
|
Term
| Use Chorpropamide cautiously in ____ and patients with ___ ro _____ impairment |
|
Definition
|
|
Term
| Which generation of Sulfonylureas are more potent? |
|
Definition
|
|
Term
| Which generation of Sulfonylureas has less severe/persistent hypoglycemia? |
|
Definition
|
|
Term
| What is a significant drug interatction of sulfonylureas? |
|
Definition
ETHANOL
Disulfiram-like interaction with ethanol (especially chlorpropramide)
Ethanol inhibits gluconeogenesis- can potentiate the hypoglycemic response |
|
|
Term
|
Definition
| Non-Sulfonylurea Secretogogues |
|
|
Term
|
Definition
| Non-Sulfonylurea Secretogogues |
|
|
Term
|
Definition
| [Glucophage] (Biguanide) - Anti-diabetic drug |
|
|
Term
| Metformin has ____ action, not ____, “euglycemic” |
|
Definition
Antihyperglycemic
hypoglycemic |
|
|
Term
|
Definition
no weight gain
no hypoglycemia
significant lipid lowering effect
works in patients that are insulin resistant |
|
|
Term
| Metformin Concern is ___ (but rare), contraindicated in: (3) |
|
Definition
lactic acidosis
Renal or hepatic insufficiency
Cardiac Failure
Hypoxic lung disease |
|
|
Term
| Combinations of anti-diabetic drugs combine the insulin releasing effect of ____ with increased glucose utilization & decreased hepatic glucose output of ___ |
|
Definition
|
|
Term
|
Definition
| Combination of Glyburide and Metformin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Metformin + Rosiglitazone |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| a-Glucosidase Inhibitors MOA: |
|
Definition
| Inhibit digestion of complex sugars |
|
|
Term
|
Definition
| Thiazolidinediones (TZDs) |
|
|
Term
|
Definition
| Thiazolidinediones (TZDs) |
|
|
Term
| Thiazolidinediones (TZDs) are insulin _______ |
|
Definition
|
|
Term
| Rosiglitazone & Pioglitazone (TZDs) MOA: |
|
Definition
| Bind to nuclear transcription factors involved in insulin action |
|
|
Term
|
Definition
| Increased risk of heart failure, angina, and MI. Contraindicated in Class III-IV heart failure patients. |
|
|
Term
|
Definition
synthetic amylin analog - injectable agent
"adjunct to insulin therapy" |
|
|
Term
|
Definition
Glucagon-like Peptide-1 (GLP-1) analog - injectable agent
"Adjunct to metformin or sulfonylurea or a combination" |
|
|
Term
|
Definition
| Newer GLP-1 agonist - injectable agent |
|
|
Term
| ____ has a 30% greater effect on HbA1C than Exenatide |
|
Definition
|
|
Term
|
Definition
| Dipeptidyl Peptidase-4 Inhibitors |
|
|
Term
|
Definition
| Dipeptidyl Peptidase-4 Inhibitors |
|
|
